EVO

MKT CAP:$1B

Evotec SE

Market Cap

$1B

Healthcare·Drug Manufacturers - Specialty & Generic·🇩🇪 Germany·NASDAQ

Healthcare·Drug·🇩🇪·NASDAQ

Stock Price

$3.23+$0.05 (+1.57%)

Apr 23, 2026

Company Details

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of ...

CEO

Christian Wojczewski

IPO Date

Feb 5, 2004

Website

www.evotec.com

Key Metrics TTM

Revenue

$919M

-2.2% YoY

Net Income

-$121M

EPS (Diluted)

-$0.34

Free Cash Flow

-$108M

Revenue / Share

$2.59

Gross Margin

14.4%

Operating Margin

-8.7%

Net Margin

-13.2%

FCF Margin

-11.7%

P/S

1.2x

P/E

—

Earnings Reports

Q1 2026

May 6, 2026

PENDING

FY 2025

Apr 8, 2026

$885M-5.0%EPS -$0.33

Q4 2025

Apr 8, 2026

$293M+13.4%EPS $0.05

Q3 2025

Sep 30, 2025

$192M-11.4%EPS -$0.14

Q2 2025

Aug 13, 2025

$200MEPS -$0.14

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 21	$156M	$36M	$8M
Q2 21	$162M	$30M	$2M
Q3 21	$187M	$50M	$21M
Q4 21	$219M	$61M	$17M
Q1 22	$193M	$38M	$541.3K
Q2 22	$201M	$36M	-$4M
Q1 23	$250M	$62M	$15M
Q2 23	$199M	$54M	-$42M
Q3 23	$229M	$44M	-$14M
Q4 23	$235M	$44M	-$14M
Q3 24	$216M	$21M	-$31M
Q4 24	$259M	$54M	$8M
Q1 25	$234M	$32M	-$23M
Q2 25	$200M	$10M	-$32M
Q3 25	$192M	-$72.5K	-$52M
Q4 25	$293M	$91M	$28M

Valuation

Quarter	P/S	P/E
Q1 21	9.4x	115.8x
Q2 21	11.9x	57.4x
Q3 21	12.9x	29.9x
Q4 21	11.5x	32.9x
Q1 22	6.8x	49.3x
Q2 22	5.7x	2415.0x
Q1 23	4.4x	—
Q2 23	4.7x	—
Q3 23	3.8x	—
Q4 23	3.9x	—
Q3 24	1.5x	—
Q4 24	3.3x	—
Q1 25	2.5x	—
Q2 25	3.3x	—
Q3 25	1.4x	—
Q4 25	1.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 21	$3M	-$40M
Q2 21	$45M	$3M
Q3 21	$24M	-$8M
Q4 21	$71M	$49M
Q1 22	$74M	$24M
Q2 22	$207M	$162M
Q1 23	$731.9K	-$50M
Q2 23	-$9M	-$80M
Q3 23	$24M	-$29M
Q4 23	$23M	-$51M
Q3 24	$50M	$17M
Q4 24	$87M	$57M
Q1 25	-$37M	-$63M
Q2 25	$31M	$3M
Q3 25	-$79M	-$103M
Q4 25	$71M	$54M

Capital Expenditures

Quarter	CapEx
Q1 21	$42M
Q2 21	$42M
Q3 21	$32M
Q4 21	$22M
Q1 22	$50M
Q2 22	$45M
Q1 23	$50M
Q2 23	$71M
Q3 23	$54M
Q4 23	$74M
Q3 24	$33M
Q4 24	$29M
Q1 25	$26M
Q2 25	$28M
Q3 25	$24M
Q4 25	$17M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 21	+11.5%	+22.3%
Q2 21	+23.9%	+25.7%
Q3 21	+23.4%	+25.5%
Q4 21	+33.1%	+35.2%
Q1 22	+23.7%	+30.0%
Q2 22	+24.6%	+28.7%
Q1 23	+33.8%	+41.7%
Q2 23	-9.0%	+20.0%
Q3 23	+19.2%	+27.0%
Q4 23	+16.9%	+21.0%
Q3 24	-13.4%	+5.1%
Q4 24	+29.9%	+3.8%
Q1 25	+1.9%	+5.5%
Q2 25	-14.9%	-6.5%
Q3 25	-11.4%	-1.4%
Q4 25	+13.4%	+5.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 21	$0	0.0%
Q2 21	$0	0.0%
Q3 21	$0	0.0%
Q4 21	$0	0.0%
Q1 22	$0	0.0%
Q2 22	$0	0.0%
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$11M	4.8%
Q3 24	$0	0.0%
Q4 24	$0	0.0%
Q1 25	$0	0.0%
Q2 25	$0	0.0%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 21	$22M	$25M	—	—
Q2 21	$20M	$29M	—	—
Q3 21	$21M	$29M	—	—
Q4 21	$14M	$29M	$11M	—
Q1 22	$21M	$37M	—	—
Q2 22	$22M	—	—	$42M
Q1 23	$22M	—	—	$50M
Q2 23	$14M	—	—	$53M
Q3 23	$20M	—	—	$46M
Q4 23	$11M	—	—	$49M
Q3 24	$14M	—	—	$54M
Q4 24	$11M	—	—	$58M
Q1 25	$13M	—	—	$56M
Q2 25	$10M	—	—	$49M
Q3 25	$10M	—	—	$49M
Q4 25	$11M	—	—	$51M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$772M	$227M	$1000M
Q2 22	$852M	$233M	$1.1B
Q3 22	$531M	$412M	$943M
Q4 22	$468M	$358M	$827M
Q1 23	$0	$1.7B	$1.7B
Q2 23	$586M	$205M	$792M
Q3 23	$618M	$141M	$759M
Q4 23	$597M	$109M	$706M
Q1 24	$541M	$103M	$644M
Q2 24	$278M	$96M	$374M
Q3 24	$302M	$94M	$396M
Q4 24	$358M	$106M	$464M
Q1 25	$360M	$109M	$469M
Q2 25	$368M	$110M	$478M
Q3 25	$203M	$74M	$277M
Q4 25	$489M	$68M	$557M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 21	328M	+8.7%	+8.7%
Q2 21	329M	+0.1%	+8.8%
Q3 21	329M	+0.1%	+8.9%
Q4 21	345M	+5.0%	+14.3%
Q1 22	353M	+2.3%	+7.7%
Q2 22	353M	0.0%	+7.5%
Q1 23	354M	+0.1%	+7.5%
Q2 23	354M	-0.0%	+2.5%
Q3 23	354M	0.0%	+0.1%
Q4 23	354M	+0.0%	+0.1%
Q3 24	355M	+0.2%	+0.2%
Q4 24	355M	+0.0%	+0.2%
Q1 25	355M	+0.1%	+0.3%
Q2 25	355M	+0.0%	+0.4%
Q3 25	355M	+0.0%	+0.2%
Q4 25	355M	+0.0%	+0.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 21	$1M	147
Q2 21	$1M	147
Q3 21	$1M	147
Q4 21	$52.1K	4K
Q1 22	$45.9K	4K
Q2 22	$48.0K	4K
Q1 23	$50.4K	5K
Q2 23	$40.2K	5K
Q3 23	$46.3K	5K
Q4 23	$45.6K	5K
Q3 24	$41.9K	5K
Q4 24	$53.6K	5K
Q1 25	$48.4K	5K
Q2 25	$41.5K	5K
Q3 25	$39.7K	5K
Q4 25	$64.4K	5K

Revenue / Employee